Conditions: Diabetes Mellitus, Type 2
Keywords: Pioglitazone HbA1c Diabetes mellitus
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 334
Healthy volunteers: no

Brief summary:
This is a dose-ranging study that will evaluate the efficacy, safety and tolerability of a range of doses of investigational product and pioglitazone, compared to placebo, administered as monotherapy over 12 weeks in treatment naive patients with T2DM

Detailed description:

Arms:
arm 1: GSK189075 arm 2: Placebo arm 3: pioglitazone (active control)

Interventions: intervention 1: GSK189075 intervention 2: pioglitazone intervention 3: Placebo
Intervention descriptions: intervention 1: Experimental Drug intervention 2: Active Control intervention 3: Placebo Comparator

Protocol document: